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Abstract
Summary We compared the patterns of osteoporosis med-
ication prescribing between two provinces in Canada with
different public drug coverage policies. Oral bisphospho-
nates were the primary drugs used, yet access to the second-
generation oral bisphosphonates (alendronate, risedronate)
was limited in one region. Implications of differential
access to oral bisphosphonates warrants further study.
Introduction Approved therapies for treating osteoporosis
in Canada include bisphosphonates, calcitonin, denosumab,
raloxifene, and teriparatide. However, significant variation
in access to these medications through public drug coverage
exists across Canada. We sought to compare patterns of
osteoporosis medication prescribing between British Co-
lumbia (BC) and Ontario.
Methods Using dispensing data from BC (PharmaNet) and
Ontario (Ontario Drug Benefits), we identified all new
users of osteoporosis medications aged 66 or more years
from 1995/1996 to 2008/2009. We summarized the number
of new users by fiscal year, sex, and index drug for each
province. BC data were also stratified by whether drugs
were dispensed within or outside public PharmaCare.
Results We identified 578,254 (n=122,653 BC) eligible new
users. Overall patterns were similar between provinces: (1)
most patients received an oral bisphosphonate (93% in BC
and 99% in Ontario); (2) etidronate prescribing declined after
2001/2002, reaching a low of 41% in BC and 10% in
Ontario in 2008/2009; and (3) the proportion of males treated
increased over time, from 7% in 1996/1997 to 25% in 2008/
2009. However, we note major differences within versus
outside the BC PharmaCare system. In particular, <2% of
drugs dispensed within PharmaCare compared to 79% of
drugs dispensed outside PharmaCare were for a second-
generation bisphosphonate (alendronate or risedronate).
Conclusions Oral bisphosphonates are the primary drugs
used to treat osteoporosis in Canada. Prescribing practices
changed over time as newer medications came to market,
yet access to second-generation bisphosphonates through
BC PharmaCare was limited. Implications of differential
access to oral bisphosphonates warrants further study.
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Introduction
Approved therapies for treating osteoporosis in Canada
include bisphosphonates (alendronate, etidronate, risedro-
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DOI 10.1007/s00198-011-1771-2nate, and zoledronic acid), calcitonin, denosumab, ralox-
ifene, and teriparatide [1]. Each drug is effective in
reducing vertebral fracture risk; however, only selected
bisphosphonates (alendronate, risedronate, and zoledronic
acid), denosumab, and teriparatide have demonstrated
significant reductions in nonvertebral fracture risk com-
pared to placebo [2, 3]. Consequently, Canadian osteopo-
rosis practice guidelines recommend etidronate, calcitonin,
and raloxifene in a list of second-line options [1]. In
contrast to practice guidelines, many publicly funded drug
plans across Canada limit coverage for first-line therapies,
yet provide unrestricted coverage for etidronate—a second-
line therapy [4].
We used data from British Columbia (BC) and
Ontario to compare osteoporosis treatment prescribing
practices between provinces. In BC, etidronate is the
only osteoporosis medication listed under general bene-
fits on its provincial drug formulary (PharmaCare). In
Ontario, etidronate has been available without restriction
since 1996, while alendronate and risedronate were
initially subject to limited access criteria until 2007,
when coverage broadened to include all three oral
bisphosphonates without restriction. Other osteoporosis
therapies are not listed on either public formulary or are
only available under restricted conditions. We hypothe-
sized that prescribing patterns would change over time
as new osteoporosis therapies became available and as
access through public drug plans broadened.
Methods
The PharmaNet database in BC includes all prescriptions
dispensed in community pharmacies since April 1991.
PharmaNet includes a field that differentiates between
claims accepted for PharmaCare (BC public drug plan)
coverage from those paid through private insurance or out-
of-pocket. In Ontario, only claims processed through the
provincial public drug plan (Ontario Drug Benefits) were
identifiable—these include drugs listed in the provincial
formulary (Table 1) for all residents aged 65 or more years
[5, 6].
Within each provincial pharmacy database, we identified
the first dispensing date of an eligible osteoporosis
medication (alendronate, cyclical etidronate, risedronate,
raloxifene, nasal calcitonin, teriparatide, zoledronic acid).
The first date an eligible osteoporosis medication was
dispensed was considered the index date, and each person
was identified only once. Given that Ontario drug data only
include persons aged 65 or more years, we restricted
inclusion to persons aged 66 or more years so that we
could compare prescribing patterns between provinces
among similarly aged patients and with at minimum 1 year
of data to identify new users. We also excluded patients
with more than one eligible osteoporosis medication
dispensed at index, and those with use of a nonosteoporosis
formulation or Paget’s disease diagnosis within the 365 days
prior to their index date.
The number of new users was examined by fiscal year,
sex, and index drug within each province. BC data were
also stratified by whether or not the index drug was
accepted by PharmaCare. At the time of analysis, we had
complete data from April 1995 to March 2009 in BC and
Ontario.
Results
We identified 578,254 (122,653 BC and 455,601
Ontario) eligible new users (Fig. 1). Overall patterns of
prescribing were similar between provinces: (1) most
patients received an oral bisphosphonate (93% in BC and
99% in Ontario); (2) etidronate prescribing declined after
2001/2002, reaching a low of 41% in BC and 10% in
Ontario in 2008/2009; and (3) the proportion of males
treated increased over time, from 7% in 1996/97 to 25% in
2008/2009 (Fig. 2). Of interest, dispensing of new
osteoporosis medications tended to occur a year earlier
in BC than Ontario. For example, etidronate and daily
alendronate both received notice of compliance in 1995
(Table 1) and were first dispensed in BC in 1995/1996
compared to 1996/1997 in Ontario. We also identified
major differences in osteoporosis medications dispensed
within versus outside the BC PharmaCare system (Fig. 3).
In particular, <2% of drugs dispensed within PharmaCare
compared to 79% of drugs dispensed outside PharmaCare
in BC were for a second-generation bisphosphonate
(alendronate or risedronate).
The use of raloxifene, teriparatide, and zoledronic acid
was low in both provinces. Raloxifene had a temporary
increase in use at time of entry into the market around 2000
and then quickly declined as weekly bisphosphonates came
to market in 2002. We document fewer than 20 teriparatide
users and fewer than 210 users of zoledronic acid in BC
and Ontario combined. We also identified little calcitonin
use in Ontario (less than 1% during the study period) yet
note that calcitonin was dispensed to a similar number of
patients since 2000/2001 in BC, with about 600 new
patients treated with nasal calcitonin as their first osteopo-
rosis medication annually.
Discussion
Prescribing practices of osteoporosis medication have
c h a n g e do v e rt i m ei nr e s p o n s et on e w l ya p p r o v e dd r u g s
1476 Osteoporos Int (2012) 23:1475–1480Table 1 Notice of compliance dates for osteoporosis medications and current public formulary listing status in British Columbia and
Ontario [5, 11]
Drug Strength Regimen Notice of
compliance
a
BC PharmaCare
listing status
Ontario Drug Benefit
Formulary listing status
Bisphosphonate
Etidronate and calcium 400/500 mg tab 14 days oral etidronate
then 76 days oral calcium
19 Jul 1995 General benefits
(since 1995)
General benefits
(since 1996)
Alendronate 10 mg tab Daily—oral 18 Dec 1995 Limited coverage
b General benefits
(since January
2007)
c
70 mg tab Weekly—oral 04 Feb 2002
Risedronate 5 mg tab Daily—oral 17 Jul 2000 Limited coverage
b General benefits
35 mg tab Weekly—oral 09 Dec 2002 (since June 2007)
c
75 mg tab Monthly—oral
(2 consecutive days)
17 Jul 2007 Not listed Not listed
150 mg tab Monthly—oral 24 Sep 2008 Not listed General benefits
(since July 2010)
Zoledronic acid 5 mg/100 ml Annual infusion 29 Oct 2007 Not listed Limited coverage
d
Other
Calcitonin 200 U/spr Daily—nasal spray 01 Sep 1999 Not listed Limited coverage
e
Denosumab 60 mg/ml Semi-annual injection 06 Aug 2010 Not listed Not listed
Raloxifene 60 mg tab Daily—oral 06 Nov 1998 Limited coverage
f Limited coverage
g
Teriparatide 250 μg/ml Daily—subcutaneous injection 03 Jun 2004 Not listed Not listed
General benefits covered without restriction, Limited coverage covered if specific clinical criteria have been met, Not listed not covered unless
approved through Individual Clinical Review
aNotice of compliance dates provided only for the first available dosing of each agent. We have not included oral bisphosphonate combination
therapy
bAvailable through special authority: clinical or radiographically documented fracture due to osteoporosis or patients who are receiving or
expected to receive the equivalent of 7.5 mg/day of prednisone equivalent for 90 consecutive days or longer
cLimited use history, Nov 2000 (alendronate) and Mar 2001 (risedronate): failed
g etidronate therapy or experience intractable side effects with
etidronate or documented allergy which precludes continuation with etidronate therapy; Apr 2003 (alendronate/risedronate): above or two of the
following three criteria: (1) bone mineral density T-score <−3.0, (2) aged 75 or more years, and (3) prior osteoporosis-related fracture
dAvailable under the exceptional access program: treatment of osteoporosis in persons unable to absorb or take oral products
eAvailable under the exceptional access program: treatment of osteoporosis in persons who have failed
g, experienced intractable side effects to or
have contraindication to all of the available Formulary alternatives (oral bisphosphonate and if patient is female raloxifene)
fAvailable through special authority: clinical or radiographically documented fracture due to osteoporosis or unsatisfactory clinical response,
defined as a new fragility fracture after 1 year adherence to alendronate or risedronate
gFailed: continued loss of bone mineral density of more than 3% after 2 years of therapy, new fracture after 1 year of therapy
Osteoporosis (OP) drug prescription dispensed,  
1 April 1995 to 31 March 2009, British Columbia 
(n=226,960) 
Osteoporosis (OP) drug prescription dispensed,  
1 April 1995 to 31 March 2009, Ontario 
(n=569,725) 
Excluded (n=104,307)* 
Age < 66 years at index (n=93,100) 
Non-OP drug formulation (n=13,066) 
Paget’s disease (n=2,806) 
Invalid sex code (n=331) 
>1 OP drug at index (n=959) 
Eligible patients dispensed incident osteoporosis 
drug, British Columbia (n=122,653) 
Female (n=102,448) 
Male (n=20,205) 
Excluded (n=114,124)* 
Age < 66 years at index (n=99,160) 
Non-OP drug formulation (n=14,140) 
Paget’s disease (n=1,091) 
Invalid sex code (n=0) 
>1 OP drug at index (n=778) 
Eligible patients dispensed incident osteoporosis 
drug, Ontario (n=455,601) 
Female (n=381,695) 
Male (n=73,906) 
Fig. 1 Study flow diagram. Osteoporosis drugs were bisphosphonates
(alendronate, 5, 10, or 70 mg; cyclical edidronate; risedronate, 5, 35,
75, or 150 mg; zoledronic acid 5 mg/100 ml); nasal calcitonin
(200 U); raloxifene; or teriparatide. Denosumab was approved in 2010
and thus is not included in this study. First date of eligible drug
prescription defined entry, participants were permitted to enter the
cohort only once and thus the data capture the first prescription for
eligible osteoporosis treatment. Asterisk may meet more than one
exclusion criterion
Osteoporos Int (2012) 23:1475–1480 1477entering the market and changes in listing status on
provincial drug formularies. Oral bisphosphonates have
dominated treatment and follow evidence-based guide-
lines [7–9]. Despite drug availability in Canada, differen-
tial coverage through provincial public drug plans for
seniors has limited access to some agents. In particular, we
identify that when not restricted by a public drug plan
formulary, physicians prefer to prescribe second-
generation (alendronate or risedronate) oral bisphospho-
nates. This is evidenced by drugs dispensed outside BC
PharmaCare and the quick convergence to weekly
bisphosphonates once coverage for alendronate and
risedronate broadened in Ontario.
Although we document differences in treatment with
second-generation bisphosphonates in BC based on
public formulary listing status, we cannot claim dispar-
ity in access to effective osteoporosis medication. The
discrepancy in listing status is related to the price
differential between agents, with etidronate being the
least expensive. The annual cost before dispensing fees
for generic medications paid through the Ontario Drug
Benefits Plan is approximately $80 for cyclical etidro-
nate and $130 for weekly alendronate or risedronate [5].
With a $50 annual difference, every 20,000 users of
alendronate or risedronate instead of etidronate costs the
public system $1 million. The difference in costs between
agents may be justifiable if one agent is more effective at
reducing fracture risk. However, little comparative effec-
tiveness data are available to support the superiority of any
of the oral bisphosphonates in reducing fracture risk. To
our knowledge, only a single study has directly compared
the effects of etidronate to alendronate or risedronate in
reducing fracture risk [10]. Authors found little difference
in hip fracture rates within 2 years between female fracture
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Fig. 2 Number of patients dis-
pensed incident osteoporosis
medication from April 1995/
March 1996 to April 2008/
March 2009, by sex (white bar
female; gray bar male) and drug
type (line graph); residents aged
66 or more years in a British
Columbia and b Ontario
1478 Osteoporos Int (2012) 23:1475–1480patients receiving etidronate compared to alendronate or
risedronate (HR=1.0, 95%; CI=0.6–1.6) [10]. More data
are needed to clarify the comparative effectiveness of oral
bisphosphonates in reducing fracture risk. Many provinces
in Canada continue to restrict access to alendronate and
risedronate through public drug plans. In the absence of
clear evidence of superiority compared with etidronate—
despite differences between agents based on placebo-
controlled trials—it may be difficult for policy makers to
justify the additional costs to the public healthcare system
by covering second-generation bisphosphonates without
restriction.
Our study is subject to some limitations. First, we
w e r el i m i t e dt op u b l i c l yf u n d e dd r u gc l a i m si nO n t a r i o ,
restricting us from assessing drugs dispensed yet
processed through private insurance or out-of-pocket.
Thus, we are limited in ability to assess the use of
medications that are not listed on the Ontario formulary
such as calcitonin, teriparatide, and zoledronic acid, as
well as alendronate and risedronate dispensing outside
the public plan. Second, we are limited to pharmacy
claims data and do not have a record of medications
prescribed yet not dispensed in community pharmacies.
Despite these limitations, our study has significant
strength. We were able to generate temporal trends in
drug dispensing patterns and identify significant differ-
ences in osteoporosis pharmacotherapy between prov-
inces in Canada related to drug coverage policies. BC
recently broadened coverage for alendronate (November
2009) and risedronate (January 2011) to remove the
need for a prior trial of etidronate. However, access to
these second-generation bisphosphonates through BC
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Fig. 3 Number of patients dis-
pensed incident osteoporosis
medication from April 1995/
March 1996 to April 2008/
March 2009, by sex (white bar
female, gray bar male) and drug
type (line graph); residents aged
66 or more years in British
Columbia a within PharmaCare
and b outside PharmaCare
Osteoporos Int (2012) 23:1475–1480 1479PharmaCare still requires clinical or radiographically
confirmed fracture or long-term glucocorticoid use.
Our results identify that physicians prefer to prescribe
following evidence-based guidelines that rank treatment as
first-line (e.g., alendronate, risedroante) or second-line (e.g.,
etidronate) based on placebo-controlled efficacy in reducing
fracture risk, with a shift toward alendronate and risedro-
nate when available. Better evidence regarding the com-
parative effectiveness of oral bisphosphonates is needed to
inform drug policy decision making in Canada. At this
time, it is difficult to claim inequity in access to effective
bone-sparing medications in Canada, yet it is interesting to
note that differences in public access to guideline-
recommended first-line treatment exist. The implications
of differential access to oral bisphosphonates warrants
further study.
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